UNSPSC 51183613: Insulin glulisine

This classification denotes a therapeutic insulin with the molecular formula C258H384N64O78S6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7XIY785AZD, chemically known as insulin (ox), 8a-l-threonine-10a-l-isoleucine-30b-l-threonine- but more generally known as insulin, which bears US NIH Compound Identifier 16129672. European Medicines Agency schedules Insulin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02689MIG.

UNSPSC 51183613 Insulin glulisine is a Commodity code representing a rapid-acting insulin product that state and local government procurement offices acquire primarily through multistate cooperative purchasing agreements for distribution to public health systems, corrections facilities, and other government-operated medical programs. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP issued in January 2026 demonstrates how state and local buyers source pharmaceutical products: manufacturers must supply insulin glulisine and related products through authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson), maintain cGMP and Drug Supply Chain Security Act compliance, carry insurance coverage including $5 million commercial general liability and $2 million network security liability, and submit detailed product information with National Drug Codes, SKUs, UPCs, strength, dosage form, and packaging configurations. The code reflects demand from state health departments, county health systems, correctional agencies, and public hospital networks that rely on cooperative purchasing vehicles to negotiate volume pricing and ensure supply security across multiple jurisdictions.

MMCAP, administered by the Minnesota Department of Administration's Office of State Procurement and including participating entities in Oregon and other states, posted the generic multi-source pharmaceuticals RFP on January 20, 2026, with proposals due March 26, 2026. The evaluation heavily weights price competitiveness (75 percent), with smaller components for fixed pricing (10 percent), EDI capability (5 percent), administrative fee compliance (5 percent), and format compliance (5 percent). Awarded vendors will supply through authorized wholesalers effective July 1, 2026, and are subject to a 3 percent administrative fee on all contract purchases plus performance penalties ranging from $200 to $1,500 per violation. The RFP does not disclose specific award values or budget ranges, but the cooperative purchasing model typically covers multiple states and counties, making scale significant for vendors able to meet manufacturing and logistics requirements within the May 15, 2026 product-availability deadline.